Background. Collaborative care is an effective intervention for depression which includes both organizational and patient-level intervention components. The effect in the UK is unknown, as is whether cluster- or patient-randomization would be the most appropriate design for a Phase III clinical trial.
Method. We undertook a Phase II patient-level randomized controlled trial in primary care, nested within a cluster-randomized trial. Depressed participants were randomized to 'collaborative care'- case manager-coordinated medication support and brief psychological treatment, enhanced specialist and GP communication - or a usual care control. The primary outcome was symptoms of depression (PHQ-9).
Results. We recruited 114 participants, 41 to the intervention group, 38 to the patient-randomized control group and 35 to the cluster-randomized control group. For the intervention compared to the cluster control the PHQ-9 effect size was 0.63 (95 % CI 0.18-1.07). There was evidence of substantial contamination between intervention and patient-randomized control participants with less difference between the intervention group and patient-randomized control group (-2.99, 95 % CI -7.56 to 1.58, p = 0.186) than between the intervention and cluster-randomized control group (-4.64, 95 % Cl -7.93 to -1.35, p = 0.008). The intra-class correlation coefficient for our primary outcome was 0.06 (95 % CI 0.00-0.32).
Conclusions. Collaborative care is a potentially powerful organizational intervention for improving depression treatment in UK primary care, the effect of which is probably partly mediated through the organizational aspects of the intervention. A large Phase III cluster-randomized trial is required to provide the most methodologically accurate test of these initial encouraging findings.
|Number of pages||9|
|Publication status||Published - Feb 2008|
- collaborative care
- complex intervention
- primary care
- randomized controlled trial
- ANTIDEPRESSANT MEDICATION
- BEHAVIORAL ACTIVATION